Recent Updates
Recently added Catalysts

Measles-mumps-rubella-varicella vaccine

Phase 3

Meningococcal Meningitis | Monoclonal antibody | Infectious Disease |Sanofi|Last Updated: May 16, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment1,378
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00483574Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersPHASE3 COMPLETED 1,378May 1, 2007Apr 1, 2009May 16, 201679 United States, Chile
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With at Least One Solicited Injection Site Reaction or Systemic Reaction Following Vaccination.
Day 0 to 7 Post-vaccination

Solicited injection site reactions: tenderness, Erythema (Redness), and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability

Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Group 1: Menactra® and Routine Pediatric VaccinesEXPERIMENTALParticipants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella \[MMRV: ProQuad\], pneumococcal conjugate \[PCV\], and hepatitis A \[HepA\]) at age 12 months.
Group 2: Routine Pediatric VaccinesOTHERParticipants received routine pediatric vaccines (measles-mumps-rubella-varicella \[MMRV: ProQuad\], pneumococcal conjugate\[PCV\], and hepatitis A \[HepA\]) at age 12 months.
Interventions
NameTypeDescription
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid ConjugateBIOLOGICAL0.5 mL, IM at age 9 and 12 months
Measles-mumps-rubella-varicella vaccineBIOLOGICAL0.5 mL, intramuscular at 12 months of age
Routine paediatric vaccine - Pneumococcal conjugate (PCV)BIOLOGICAL0.5 mL, Intramuscular at age 12 months
Routine paediatric vaccine - Hepatitis ABIOLOGICAL0.5 mL, Intramuscular at age 12 months
Unlock Study Design Details
Eligibility Criteria
Age Range9 Months — 12 Months
SexALL
Healthy VolunteersYes
Study Sites79

Inclusion Criteria : * Healthy, as determined by medical history and physical examination * Aged 9 months (249 to 305 days) or 12 months (365 to 400 days) at the time of enrollment * The parent or legal guardian has signed and dated the Independent Ethics Committee (IEC)-/Institutional Review Board...

Countries:United StatesChile
Unlock Eligibility Criteria